Chris Roberts jumps back into biotech with CSO gig at Black Diamond; Troubled Five Prime appoints interim CEO
→ After spending two years as entrepreneur-in-residence at SR One — the venture arm of his former employer, GlaxoSmithKline — Chris Roberts is back at the frontlines of biotech.
As CSO of Black Diamond Therapeutics, Roberts joins CEO David Epstein in driving their targeted kinase inhibitors toward the clinic. He will lead research and early development on the biotech’s MAP platform, which zeroes in on allosteric mutations of oncogenes. Its lead candidate, BDTX-189, targets EGFR and HER2 regardless of tumor type.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
